
    
      Neoadjuvant chemotherapy(NAC) is traditionally for locally advanced disease, converting an
      inoperable to a resectable tumor.In recent years, it has become an option for patients of
      lower tumor stage to increase the possibility of breast conserving therapy. An effective
      method to monitor the response to NAC is important.
    
  